PubRank

Paul J Pockros

Author PubWeight™ 77.42‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 16.21
2 Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014 9.45
3 Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014 7.73
4 All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015 3.96
5 Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006 3.92
6 The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004 2.47
7 Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004 2.28
8 Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med 2015 2.13
9 Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. J Hepatol 2012 2.05
10 Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. J Hepatol 2013 1.68
11 Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 2008 1.66
12 Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int 2008 1.56
13 Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 2002 1.43
14 Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004 1.42
15 Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev 2003 1.28
16 Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology 2007 1.23
17 Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology 2012 1.20
18 Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006 1.12
19 Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 2003 1.09
20 HCV RNA viral load assessments in the era of direct-acting antivirals. Am J Gastroenterol 2013 1.02
21 Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol 2006 0.94
22 A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results. Hepatology 2009 0.93
23 Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol 2011 0.90
24 Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study. Liver Int 2014 0.85
25 Comparison of esophageal capsule endoscopy and esophagogastroduodenoscopy for diagnosis of esophageal varices. World J Gastroenterol 2008 0.83
26 The clinical utility of using Catrimox-14-treated whole blood in detecting hepatitis C virus RNA. Antivir Ther 2005 0.82
27 Simeprevir for the treatment of chronic hepatitis C. Expert Opin Pharmacother 2013 0.81
28 Chronic hepatitis C virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells. Clin Vaccine Immunol 2012 0.80
29 Aspergillosis in liver transplant recipients: successful treatment and improved survival using a multistep approach. South Med J 2002 0.80
30 Hematologic and oncologic diseases and the liver. Clin Liver Dis 2011 0.79
31 Why do we need another interferon? Gastroenterology 2010 0.78
32 A Src family kinase inhibitor improves survival in experimental acute liver failure associated with elevated cerebral and circulating vascular endothelial growth factor levels. Liver Int 2011 0.77
33 Ribavirin analogs. Clin Liver Dis 2009 0.77
34 An Unexpected Pulmonary Complication Following Transcatheter Arterial Chemoembolization of a Small Hepatocellular Carcinoma. J Clin Gastroenterol 2016 0.76
35 SCV-07 (SciClone Pharmaceuticals/Verta). Curr Opin Investig Drugs 2006 0.76
36 Drug-induced liver injury from antiepileptic drugs. Clin Liver Dis 2013 0.76
37 How should hepatitis C be managed in patients aged 65 years and older? Nat Clin Pract Gastroenterol Hepatol 2007 0.75
38 Noninvasive markers of fibrosis in chronic hepatitis patients. J Clin Gastroenterol 2006 0.75
39 Drugs in development for viral hepatitis: care and caution. Drugs 2011 0.75
40 Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. Eur J Gastroenterol Hepatol 2016 0.75